New York, NY: An $11.75 million settlement has been tentatively agreed in the Wellbutrin XL antitrust class action filed against Valeant Pharmaceuticals International Inc, and GlaxoSmithKline (GSK). If you bought Wellbutrin XL® or its Generic equivalent, the proposed class action settlement could affect you.
This matter is a lawsuit against Valeant Pharmaceuticals, Inc., formerly Biovail Corp. ("Biovail"), and SmithKline Beecham Corporation doing business as GlaxoSmithKline and GlaxoSmithKline plc (collectively "GSK") (together with Biovail, "Defendants"), the companies that manufactured and marketed the antidepressant Wellbutrin XL.
The lawsuit, entitled In re: Wellbutrin XL Antitrust Litigation, Case No. 8-cv-2433, U.S. District Court, Eastern District of Pennsylvania, alleges the pharmaceutical manufacturers worked together to delay the availability of less expensive, generic versions of Wellbutrin XL. Anyone who purchased Wellbutrin XL or its generic equivalent in the following states may be eligible to claim part of the settlement, if it is approved: California, Florida, Nevada, New York, Tennessee and/or Wisconsin.
For additional information regarding this lawsuit, proposed settlement, and for obtaining a Claim, visit: http://www.wxlclassaction.com/.